No clear benefits of generic prescribing, says Denmark’s Lif

The Danish Medicines Agency's new analysis shows that generic prescribing will not necessarily lead to financial savings or increased patient safety. On the contrary, a two-tier prescribing system can create unnecessary complexity and potential risks – a conclusion that Denmark’s pharma trade group Lif supports.

The Lif also pointed out that the current model for generic substitution already ensures low prices and high patient safety for Danish patients.

The Danish Medicines Agency's new analysis of generic prescribing confirms that the current model for generic substitution works extremely effectively in Denmark, despite a perception that generic prescribing can lower the regions' costs for subsidized medicines.